IFNB1 and myeloid sarcoma: In addition, IFN-β treatment in patients with MS leads to increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1), which subsequently leads to a significant decrease in VLA-4 expression on lymphocytes, interfering with their capacity to bind endothelial cells thereby preventing their diapedeses through the BBB (68).